Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas9-mediated genome editing of the thymidine kinase gene in a clinical HSV-1 isolate identifies F289S as novel acyclovir-resistant mutation.

Antiviral research - 1 Aug 2024

Zheng Shuxuan, Verjans Georges M G M, Evers Anouk, van den Wittenboer Ellen, Tjhie Jeroen H T, Snoeck Robert, Wiertz Emmanuel J H J, Andrei Graciela, van Kampen Jeroen J A, Lebbink Robert Jan

Abstract excerpt

Herpes simplex virus type 1 (HSV-1) is a neurotropic alphaherpesvirus that establishes a lifelong infection in sensory neurons of infected individuals, accompanied with intermittent reactivation of latent virus causing (a)symptomatic virus shedding. Whereas acyclovir (ACV) is a safe and highly effective antiviral to treat HSV-1 infections, long-term usage can lead to emergence of ACV resistant (ACVR) HSV-1 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acyclovir
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Drug Resistance, Viral

Share to Gene Editing

Share to Herpes Simplex

Share to Herpesvirus 1, Human

Share to Thymidine Kinase

Source

Identifiers

PMID: 38944159
DOI: 10.1016/j.antiviral.2024.105950

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas9-mediated genome editing of the thymidine kinase gene in a clinical HSV-1 isolate identifies F289S as novel acyclovir-resistant mutation.PMID 38944159Read ↗

Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in miceSemantic proximity Read ↗

Six years of clinical herpes simplex virus genotypic acyclovir resistance testing confirms common resistance mechanisms and identifies novel mutationsSemantic proximity Read ↗

A Mutation in the Herpes Simplex Virus Type 1 (HSV-1) UL29 Gene is Associated with Anti-Herpesvirus Drugs' Susceptibility.Semantic proximity Read ↗

CRISPR/Cas9, a powerful tool to target human herpesvirusesSemantic proximity Read ↗

High prevalence but low clinical impact of acyclovir-resistant herpes simplex virus type 1 infections in patients with hematologic disorders.Semantic proximity Read ↗

Clinical management of herpes simplex virus infections: past, present, and futureSemantic proximity Read ↗

Complete and Prolonged Inhibition of Herpes Simplex Virus Type 1 Infection In Vitro by CRISPR/Cas9 and CRISPR/CasX SystemsSemantic proximity Read ↗

Single AAV-Mediated CRISPR-SaCas9 Inhibits HSV-1 Replication by Editing ICP4 in Trigeminal Ganglion NeuronsSemantic proximity Read ↗

Clinical and genotypic characteristics of antiviral-resistant herpes simplex virus 1 and 2 infections: a case series.Semantic proximity Read ↗

Acyclovir-resistant HSV-1 isolates among immunocompromised patients in southern Taiwan: Low prevalence and novel mutations.Semantic proximity Read ↗

Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.Semantic proximity Read ↗

CRISPR/Cas9-Mediated Genome Editing of Herpesviruses Limits Productive and Latent InfectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.